Reports

Generics reduce costs and increase access

Home/Reports | Posted 08/01/2016

Generics reduce costs for both patients and payers and increase patient’s access to medicines, according to a report by the Germany-based Institute for Healthcare and Social Research (IGES).

Generics savings continue to climb in the US

Home/Reports | Posted 04/12/2015

Generics manufacturers have joined to celebrate the latest data from the Generic Drug Savings in the US report. According to the report, the US healthcare system saved a record US$254 billion in 2014 from generics, or US$1.68 trillion between 2005 and 2014.

Pivotal clinical trials for trastuzumab biosimilars

Home/Reports | Posted 06/11/2015

Biosimilars of Roche’s Herceptin (trastuzumab), a humanized monoclonal antibody are currently under development.

Pivotal clinical trials for rituximab biosimilars

Home/Reports | Posted 30/10/2015

Biosimilars of Roche’s MabThera/Rituxan (rituximab), a chimeric monoclonal antibody are currently under development.

German physicians not pressured to switch to biosimilar infliximab

Home/Reports | Posted 02/10/2015

Rheumatologists and gastroenterologists in Germany are not being put under pressure to switch patients from Remicade (infliximab) to biosimilar infliximab, according to a new report from research and advisory firm Decision Resources.

Pivotal clinical trials for bevacizumab biosimilars

Home/Reports | Posted 18/09/2015

Biosimilars of Roche’s Avastin (bevacizumab), a humanized monoclonal antibody, are currently under development.

Generics use in Italy could save Euros 1.4 billion per year

Home/Reports | Posted 05/06/2015

A report published by Italian generics association Assogenericion on 5 May 2015 points to the fact that generics are crucial in the containment of pharmaceutical expenditure in Italy.

Clinical programmes for oncology biosimilars

Home/Reports | Posted 28/08/2015

Biosimilars for oncology drugs are currently under development. These include biosimilars of blockbusters such as Roche’s Avastin (bevacizumab), MabThera/Rituxan (rituximab) and Herceptin (trastuzumab).

Doctors’ survey reveals lack of confidence in biosimilars

Home/Reports | Posted 21/08/2015

Online physician’s platform and community QuantiaMD survey of 300 primary care physicians and specialists in the US has found a lack of confidence concerning biosimilars.

Clinical programmes for anti-TNF biosimilars

Home/Reports | Posted 14/08/2015

Biosimilars for anti-tumour necrosis factor (anti-TNF) drugs are currently under development. These include biosimilars of blockbusters such as AbbVie’s Humira (adalimumab), Amgen’s Enbrel (etanercept) and Johnson & Johnson’s Remicade (infliximab).